Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

So maybe my friend who refused to go on Pradaxa because of no reversal agent might be able to change her mind.
The trial here:
https://clinicaltrials.gov/show/NCT02104947

A discussion of preliminary results here:

NOAC Antidote Promising in Phase III Trial

Idarucizumab restored clotting in most patients on the new oral anticoagulant (NOAC) dabigatran (Pradaxa) who had serious bleeding or required urgent surgery, according to interim results of the phase III RE-VERSE AD trial.
The median maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours of administration was 100%, based on central laboratory analysis of dilute thrombin time or ecarin clotting time.

Advertisement

"Idarucizumab normalized the test results in 88% to 98% of the patients, an effect that was evident within minutes," Charles V. Pollack Jr., MD, of the Pennsylvania Hospital in Philadelphia, and colleagues found.